BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo targets hard-to-treat pancreatic cancer in early trial
Disease control Recruiting nowThis study tests a new drug (HRS-4642) combined with two other drugs (nimotuzumab and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if this combination can shrink the tumor enough…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 26, 2026 06:02 UTC
-
New chemo sequence aims to shrink pancreatic tumors enough for surgery
Disease control Recruiting nowThis study is for people with pancreatic cancer that is either borderline or locally advanced, meaning it has not spread far but is hard to remove surgically. Researchers want to see if giving two different chemotherapy combinations one after the other can shrink the tumor enough…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
New hope for tough pancreatic cancers: PTM-101 trial opens
Disease control Recruiting nowThis early-phase study tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is borderline resectable or locally advanced (not yet spread to distant organs). The goal is to see if adding PTM-101 is safe and can shrink tumors …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: PanTher Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New triple attack on pancreatic cancer shows promise in early trial
Disease control Recruiting nowThis study is testing a new approach for people with pancreatic cancer that can be removed with surgery. Before surgery, patients receive a combination of chemotherapy, immunotherapy, and targeted radiation. After surgery, they continue with chemotherapy and immunotherapy. The go…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New hope for pancreatic cancer: immune boosting drug combo trial launches
Disease control Recruiting nowThis study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. The goal is to make surgery possible and improve survival. About 56 adults with u…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC